Annual Research Review: Prevention of psychosis in adolescents – systematic review and meta‐analysis of advances in detection, prognosis and intervention

Autor: Ilaria Bonoldi, Gonzalo Salazar de Pablo, Celso Arango, Aranzazu Fernandez-Rivas, Helen Baldwin, Christoph U. Correll, Paolo Fusar-Poli, Julio David Vaquerizo Serrano, Carmen Moreno, Ana Catalan, Pierluca Mosillo
Rok vydání: 2020
Předmět:
Male
clinical high-risk state for psychosis
Psychological intervention
0302 clinical medicine
prevention
ultra-high-risk
Developmental and Educational Psychology
psychosis
First episode
education.field_of_study
05 social sciences
perceived social stress
Prognosis
behavior assessment system
indicated prevention
Anxiety Disorders
Psychiatry and Mental health
young-people
Cognitive remediation therapy
Schizophrenia
Meta-analysis
randomized controlled-trial
Female
Psychology
Antipsychotic Agents
050104 developmental & child psychology
medicine.medical_specialty
Psychosis
Adolescent
Population
03 medical and health sciences
medicine
Humans
reduced prepulse inhibition
0501 psychology and cognitive sciences
first-episode
Psychiatry
education
childhood
help-seeking adolescents
psychosis risk
evidence
prediction
Publication bias
medicine.disease
Cognitive Remediation
clinical high-risk
schizophrenia
meta-analysis
Psychotic Disorders
quality-of-life
Pediatrics
Perinatology and Child Health

adolescence
030217 neurology & neurosurgery
Zdroj: Addi. Archivo Digital para la Docencia y la Investigación
instname
Catalan, A, Salazar De Pablo, G, Vaquerizo Serrano, J, Mosillo, P, Baldwin, H, Fernández-rivas, A, Moreno, C, Arango, C, Correll, C U, Bonoldi, I & Fusar-poli, P 2021, ' Annual Research Review: Prevention of psychosis in adolescents – systematic review and meta-analysis of advances in detection, prognosis and intervention ', Journal of Child Psychology and Psychiatry, vol. 62, no. 5, pp. 657-673 . https://doi.org/10.1111/jcpp.13322
Addi: Archivo Digital para la Docencia y la Investigación
Universidad del País Vasco
ISSN: 1469-7610
0021-9630
DOI: 10.1111/jcpp.13322
Popis: Background The clinical high-risk state for psychosis (CHR-P) paradigm has facilitated the implementation of psychosis prevention into clinical practice; however, advancements in adolescent CHR-P populations are less established. Methods We performed a PRISMA/MOOSE-compliant systematic review of the Web of Science database, from inception until 7 October 2019, to identify original studies conducted in CHR-P children and adolescents (mean age = 36 months.Interventions: There was not enough evidence to recommend one specific treatment (including cognitive behavioural therapy) over the others (including control conditions) to prevent the transition to psychosis in this population. Randomised controlled trials suggested that family interventions, cognitive remediation and fish oil supplementation may improve cognition, symptoms and functioning. At baseline, 30% of CHR-P adolescents were prescribed antipsychotics and 60% received psychotherapy. Conclusions It is possible to detect and formulate a group-level prognosis in adolescents at risk for psychosis. Future interventional research is required. G.S.d.P. and J.V.S. are supported by the Alicia Koplowitz Foundation. The study has been supported by the Spanish Ministry of Science, Innovation, and Universities, Instituto de Salud Carlos III, European Regional Development Fund 'A way of making Europe,' Centro de Investigacion Biomedica en Red Salud Mental, Madrid Regional Government; and Fundacion Mutua Madrilena. A.C. has received personal fees from Janssen and grant support from the Instituto de Salud Carlos III, Spanish Ministry of Economy and Competitiveness. C.A. has been a consultant to or has received honoraria or grants from Acadia, Angelini, Gedeon Richter, Janssen Cilag, Lundbeck, Otsuka, Roche, Sage, Servier, Shire, Schering Plough, Sumitomo Dainippon Pharma, Sunovion and Takeda. C.M. has acted as consultant or participated in DMC for Janssen, Servier, Lundbeck, Nuvelution, Angelini and Otsuka and has received grant support from European Union Funds and Instituto de Salud Carlos III, Spanish Ministry of Economy and Competitiviness. C.U.C. has been a consultant and/or adviser to or has received honoraria from: Alkermes, Allergan, Angelini, Boehringer-Ingelheim, Gedeon Richter, Gerson Lehrman Group, Indivior, IntraCellular Therapies, Janssen/J&J, LB Pharma, Lundbeck, MedAvante-ProPhase, Medscape, Merck, Neurocrine, Noven, Otsuka, Pfizer, Recordati, Rovi, Servier, Sumitomo Dainippon, Sunovion, Supernus, Takeda and Teva. He has provided expert testimony for Bristol-Myers Squibb, Janssen and Otsuka. He served on a Data Safety Monitoring Board for Boehringer-Ingelheim, Lundbeck, Rovi, Supernus, and Teva. He received royalties from UpToDate and grant support from Janssen and Takeda. He is also a shareholder of LB Pharma. P.F-P. has been a consultant to and received research funds from Lundbeck and received honoraria from Menarini and Angelini
Databáze: OpenAIRE
Pro tento záznam nejsou dostupné žádné jednotky.